Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza - 2The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- 37 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- 46 Exceptionally Appraised Summer Travel Objections
- 5Figure out How to Augment Your Rooftop Substitution Speculation
- Sweet Taste? Candy Fulfills You
- Vote In favor of Your #1 Electric Vehicles
- Vote In favor of Your Favored Sort Of Dress
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- 6 Famous Urban communities for Shopping on the planet
